Patents by Inventor Carlos A. Guzman
Carlos A. Guzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12042536Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: GrantFiled: January 19, 2023Date of Patent: July 23, 2024Assignees: The Governors of the University of Alberta, Helmholtz Center for Infection ResearchInventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Publication number: 20240058438Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: ApplicationFiled: January 19, 2023Publication date: February 22, 2024Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Publication number: 20230129118Abstract: Phytosphingosine derivatives suitable as adjuvants in immune stimulation, pharmaceutical compositions comprising such compounds and the medical use of the compounds and/or compositions in therapeutic or prophylactic methods of immune stimulation in a subject, and for use in the treatment of a disease, for which stimulation of an immune response in a subject produces a therapeutic benefit. The phytosphingosine derivative may also be used as adjuvants in vaccinating a subject. The phytosphingosine derivative may also be used in stimulating antibody production, stimulating an immune response against infection, stimulating an immune response against a cancer, or preventing and/or treating septic shock. Methods for the manufacture of the derivatives comprising an Ugi-4-component reaction (Ugi-4CR) is also disclosed.Type: ApplicationFiled: June 18, 2021Publication date: April 27, 2023Inventors: Yanira MENDEZ-GOMEZ, Bernhard WESTERMANN, Daniel GARCIA-RIVERA, Aldrin VASCO-VIDAL, Ludger WESSJOHANN, Carlos A. GUZMÁN, Thomas EBENSEN, Kai SCHULZE, Peggy RIESE, Stephanie TRITTEL
-
Patent number: 11576968Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: GrantFiled: December 15, 2020Date of Patent: February 14, 2023Assignee: The Governors of the University of AlbertaInventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Publication number: 20220257752Abstract: In a first aspect, the present invention relates to cyclic dinucleotide compounds, in particular, c-di AMP for use in a method of inducing or promoting an immune response in an individual wherein said individual is a neonate or infant. The compound according to the present invention is particularly useful for use in therapeutic or prophylactic vaccination. In a further aspect, pharmaceutical compositions comprising the compound according to the present invention as an adjuvant, a pharmaceutically active ingredient for use as defined herein, in particular, as an adjuvant in a vaccine for unborn children, neonates and infants are provided. Finally, the present invention relates to a kit comprising a compound according to the present invention as an adjuvant, an antigen comprising antigenic structure as active vaccination component, in particular, to the use of said kit in a use of preventing or treating a disease.Type: ApplicationFiled: August 28, 2020Publication date: August 18, 2022Inventors: Carlos A. GUZMAN, Dario LIRUSSI, Thomas EBENSEN, Sebastian Felix WEISSMANN
-
Publication number: 20210170018Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: ApplicationFiled: December 15, 2020Publication date: June 10, 2021Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Publication number: 20210030865Abstract: In a first aspect, the present invention relates to a method for determining the responsiveness of an individual to vaccination, like viral vaccination or for the determination of viral vaccine efficacy in an individual as well as a method for the stratification of the vaccination regimen, e.g. viral vaccination, in an individual based on determining the level or the amount of at least one of IL-8 or IL-18 in a sample; said sample is obtained from an individual at least once before or at least once after vaccination. The method allows to determine the vaccination regimen with the vaccine, in particular, a virus vaccine, like an influenza virus vaccine whereby when a low level of at least one of IL-8 and/or IL-18 is determined, said low level is indicative for a personalized vaccine strategy. In a further aspect, the use of at least one of IL-8 or IL-18 as a predictive marker for vaccine efficacy or immune protection by vaccination is provided.Type: ApplicationFiled: March 20, 2019Publication date: February 4, 2021Inventors: Carlos A. GUZMAN, Frank PESSLER, Peggy RIESE, Manas AKMATOV
-
Patent number: 10881726Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.Type: GrantFiled: October 5, 2017Date of Patent: January 5, 2021Assignees: The Governors of the University of Alberta, Helmholtz Center for Infection ResearchInventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
-
Patent number: 9597391Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: GrantFiled: November 8, 2006Date of Patent: March 21, 2017Assignee: HELMHOLTZ_ZENTRUM FUER INFEKTIONSFORSCHUNG GMBHInventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
-
Patent number: 8257734Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: GrantFiled: November 8, 2006Date of Patent: September 4, 2012Assignee: Helmhotlz-Zentrum Fuer Infektions-Forschung GmbHInventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
-
Publication number: 20100015215Abstract: The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours and allergies. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants.Type: ApplicationFiled: September 6, 2007Publication date: January 21, 2010Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman, Götz Milkereit
-
Publication number: 20090169609Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: ApplicationFiled: November 8, 2006Publication date: July 2, 2009Applicant: HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMGBInventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
-
Publication number: 20080286296Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: ApplicationFiled: November 8, 2006Publication date: November 20, 2008Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
-
Publication number: 20080206319Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.Type: ApplicationFiled: October 19, 2006Publication date: August 28, 2008Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
-
Patent number: 7115269Abstract: The present invention is directed to an attenuated Salmonella comprising a eukaryotic expression vector for delivery of the eukaryotic expression vector to a eukaryotic cell. Delivery may be to eukaryotic cells cultured in vitro or to cells in vivo, such as by oral administration of the attenuated Salmonella comprising the eukaryotic expression vector.Type: GrantFiled: October 18, 1999Date of Patent: October 3, 2006Assignee: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)Inventors: Ayub Darji, Carlos A. Guzman, Kenneth Timmis, Siegfried Weiss, Birgit Gerstel, Trinad Chakraborty, Petra Wachholz, Jürgen Wehland
-
Publication number: 20020106376Abstract: A common problem in human vaccinology is the limited availability of efficient and non-toxic adjuvants capable of promoting mucosal responses. The potential usefulness of fibronectin-binding protein (SfbI) of Streptococcus pyogenes as immunological adjuvant was assessed using ovalbumin (OVA) as a model antigen. Mice were immunized by intranasal route either with soluble OVA or OVA covalently coupled to SfbI. Immunization with OVA-SfbI resulted in the elicitation of about 100-fold higher titres of anti-OVA serum IgG than using OVA alone. The anti-OVA IgG subclass pattern was dominated in both groups of mice by IgG1, followed by IgG2b, IgG2a, and IgG3. Immunization with OVA-SfbI also resulted in the elicitation of OVA-specific IgA in lung washes (24% of the total IgA), which was absent in mice immunized with OVA alone. Spleen cells from OVA-SfbI immunized mice also gave a much stronger proliferative response to in vitro restimulation with soluble OVA.Type: ApplicationFiled: January 30, 2002Publication date: August 8, 2002Applicant: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)Inventors: Eva Medina, Gursharan S. Chhatwal, Carlos A. Guzman